In this large retrospective cohort of patients admitted to a non-ICU with COPD, and who received steroids within 2 days of admission, researchers found that 92% of patients were originally treated with IV steroids (and 8% with oral steroids). After propensity adjustment, they found the risk of treatment failure, LOS, and cost were all lower in those that received oral steroids. Use of oral steroids is not associated with worse outcomes than treatment with IV steroids in patients admitted with COPD (abstract).
Share This Post
Categories
Related Posts
While spring 2020 feels like a lifetime ago, COVID-19 is still with us. Unfortunately, this winter has brought more infections, hospitalizations, and death rates that eclipse what many saw last spring. But this time, while the headlines are back about hospitals running low on PPE, ICU bed shortages, and long lines for testing, we now […]
This article is part of a series in The Hospital Leader written by members of the Division of Hospital Medicine at Dell Medical School at The University of Texas in Austin, exploring lessons learned from the coronavirus pandemic and outlining an approach for creating COVID-19 Centers of Excellence. Evidence on emerging treatments for COVID-19 has […]
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Leave A Comment